Lytix and Curida: Growth and innovation
Lytix Biopharma and Curida, both Norwegian-owned, have gained attention and acclaim for their innovative approaches and substantial contributions to the healthcare sector.
Margit Selsjord is responsible for creating digital communications content for Oslo Cancer Cluster. Including articles, photographs, videos for the clusters websites and social media platforms.
Selsjord is a trained photojournalist with communications experience from e.g. LMI (The Association of the Pharmaceutical Industry) and the University of Oslo.
Lytix Biopharma and Curida, both Norwegian-owned, have gained attention and acclaim for their innovative approaches and substantial contributions to the healthcare sector.
In a great achievement, DoMore Diagnostics has been awarded the prestigious EIC Accelerator grant totalling EUR 10 million.
A new collaboration agreement between AstraZeneca, Oslo Cancer Cluster, and Oslo Science City aims to strengthen the Nordic health industry.
Meet the sponsors behind Cancer Crosslinks 2024: Bristol Myers Squibb and Daiichi-Sankyo.
Oslo Cancer Cluster is an oncology research and industry cluster dedicated to improving the lives of cancer patients by accelerating the development of new cancer diagnostics and medicines.
We are a national non-profit member organization with about 90 members. Our members are Norwegian and international companies, research and financial institutions, university hospitals and organizations – all working in the cancer field.